Current schizophrenia research is moving beyond traditional dopamine-blocking drugs. Trials are testing muscarinic receptor agonists like KarXT, which showed reduced side effects in late-stage studies. Gene therapy approaches such as AMT-260 are exploring whether modifying specific neural pathways can provide longer-lasting relief. Other studies focus on cognitive symptoms that existing medications fail to address. Many trials are available at sites across major U.S. cities. If you or a loved one has treatment-resistant schizophrenia or wants access to emerging therapies, exploring clinical trials could open new options not yet available through standard care.
Neurological
Schizophrenia Clinical Trials: Latest Treatment Options 2026
Quick Answer
Several new schizophrenia clinical trials are recruiting patients in 2026, testing next-generation antipsychotics, gene therapies, and novel mechanisms that target glutamate and muscarinic receptors rather than dopamine alone.
Take the Next Step
Find clinical trials that match your condition, location, and treatment preferences.